Zhukova N, et al. - Authors analyzed 15 cases of a median age of 7 years to evaluate the use of bevacizumab as a single agent or in combination with traditional chemotherapy regimens with unresectable or progressive low-grade glioma. They observed rapid visual improvement, resolution of endocrine symptoms and motor function improvement in most of the cases. They included the treatment-limiting toxicities like grade 4 proteinuria, hypertension and pausing of therapy plus antihypertensives and concluded bevacizumab, a tolerated and efficient remedy for rapid tumor control to preserve the vision and improve morbidity.